Sight SciencesSGHT +1.43%72 5-Year Yield-on-Cost % is 0.00 as of Jul. 12, 2026. GuruFocus rates SGHT with a GF Score™ of 72/100 and a GF Value™ of $4.51 (Modestly Overvalued). The stock has 3 warning signs investors should review. Among 327 Medical Devices & Instruments companies, Sight Sciences ranks worse than 305810.09% on this metric.
Sight Sciences's yield on cost for the quarter that ended in Mar. 2026 was 0.00.
The historical rank and industry rank for Sight Sciences's 5-Year Yield-on-Cost % or its related term are showing as below:
SGHT's 5-Year Yield-on-Cost % is not ranked *
in the Medical Devices & Instruments industry.
Industry Median: 2.35 * Ranked among companies with meaningful 5-Year Yield-on-Cost % only.
Of course the risk here is that the company may not raise its dividends as it did before. The key is to select the companies that can consistently raise its dividends. Usually companies with long history of raising dividends tend to do so.
Sight Sciences 5-Year Yield-on-Cost % Related Terms
SGHT vs SENS, LAB, TMCI: 5-Year Yield-on-Cost % Comparison
For the Medical Devices subindustry, Sight Sciences's 5-Year Yield-on-Cost %, along with its competitors' market caps and 5-Year Yield-on-Cost % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Sight Sciences 5-Year Yield-on-Cost % vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Sight Sciences's 5-Year Yield-on-Cost % distribution charts can be found below:
* The bar in red indicates where Sight Sciences's 5-Year Yield-on-Cost % falls into.
Dividend Yield % and dividend growth of a stock is an important factor for income investors. But if company A raises its dividend constantly faster than company B, company A's future dividend yield might be much higher than Company B's even if their yields are the same now and their stock prices do not change.
Yield on Cost assumes that you buy and the stock today, and hold it for 5 years. If the company raises it dividends at the same rate as it did over the past 5 years, the dividends investors receive annually in 5 years relative to the stock price today.
Therefore, Yield-on-Cost of Sight Sciences is calculated as
Sight Sciences (SGHT) has a 5-Year Yield-on-Cost % of 0.00 as of Jul. 12, 2026. 5-Year Yield on Cost measures the expected yield based on a company's current yield and 5-year dividend growth. View historical data on Sight Sciences and its competitors. According to the industry distribution chart, Sight Sciences ranks #999999 out of 327 companies in the Medical Devices & Instruments industry.
Is Sight Sciences' 5-Year Yield-on-Cost % too high?
Sight Sciences' current 5-Year Yield-on-Cost % is 0.00. Based on the distribution chart, Sight Sciences ranks #999999 out of 327 companies in the Medical Devices & Instruments industry, which is in the bottom quartile relative to peers. Overall, Sight Sciences has a GF Score™ of 72/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Sight Sciences' 5-Year Yield-on-Cost % compare to SENS and LAB?
According to the Medical Devices & Instruments industry distribution chart, Sight Sciences ranks #999999 out of 327 companies for 5-Year Yield-on-Cost %. This places Sight Sciences in the lower half of its industry. The industry median 5-Year Yield-on-Cost % is 2.35. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 5-Year Yield-on-Cost % for a Medical Devices & Instruments company?
The median 5-Year Yield-on-Cost % among Medical Devices & Instruments companies is 2.35, based on 327 companies in the industry. Companies in the top quartile (top 25%) have a 5-Year Yield-on-Cost % significantly above this median, while those in the bottom quartile fall well below. However, 5-Year Yield-on-Cost % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 5-Year Yield-on-Cost % mean?
A high 5-Year Yield-on-Cost % can signal that a stock is expensive relative to its fundamentals. 5-Year Yield on Cost measures the expected yield based on a company's current yield and 5-year dividend growth. View historical data on Sight Sciences and its competitors. For the Medical Devices & Instruments industry, the median 5-Year Yield-on-Cost % is 2.35 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Sight Sciences's current 5-Year Yield-on-Cost % is 0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Sight Sciences stock overvalued right now?
Based on GuruFocus' analysis, Sight Sciences (SGHT) is currently considered Modestly Overvalued. The stock's GF Value™ is $4.51, compared to a current price of $5.33 — trading 18.2% above its estimated fair value. The current 5-Year Yield-on-Cost % is 0.00. Sight Sciences' overall GF Score™ is 72/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 5-Year Yield-on-Cost % calculated?
5-Year Yield-on-Cost % is calculated from a company's financial statements. For Sight Sciences (SGHT), the current 5-Year Yield-on-Cost % is 0.00 as of Jul. 12, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Sight Sciences (SGHT) Overvalued in 2026?
Based on GuruFocus' analysis, Sight Sciences stock appears to be overvalued.
The current stock price of $5.33 is trading 18.2% above its estimated GF Value™ of $4.51.
GuruFocus considers Sight Sciences to be Modestly Overvalued.
Key valuation signals for SGHT:
5-Year Yield-on-Cost %: 0.00
GF Value™: $4.51 vs. price of $5.33 (18.2% above fair value)
No single metric tells the full story. See the SGHT stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Sight Sciences Inc is an ophthalmic medical device company focused on the development and commercialization of surgical and nonsurgical technologies for the treatment of prevalent eye diseases. The company operates through two segments: Interventional Glaucoma, which generates the majority of revenue and includes the OMNI Surgical System family of products and the SION Surgical Instrument used in minimally invasive glaucoma surgery to reduce intraocular pressure in adult patients with open-angle glaucoma; and Interventional Dry Eye, which includes the TearCare System, an interventional device designed to melt and facilitate the removal of meibomian gland obstructions and restore gland functionality in adult patients with evaporative dry eye disease.
72GF Score
Get the complete analysis for SGHT
5-Year Yield-on-Cost % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SGHT has been successfully added to your 